In this section, you can access to the latest technical information related to the FUTURE project topic.

An Antioxidant Enzyme Therapeutic for COVID?19

A catalase?based therapeutic is developed for COVID?19, which eliminates excessively produced reactive oxygen species, prevents oxidative injury, regulates production of cytokines, and represses replication of SARS?CoV?2 in ex vivo cell studies and rhesus macaques, providing a low?cost yet effective therapeutic for the pandemic and hyperinflammation in general.The COVID?19 pandemic has taken a significant toll on people worldwide, and there are currently no specific antivirus drugs or vaccines. Herein it is a therapeutic based on catalase, an antioxidant enzyme that can effectively breakdown hydrogen peroxide and minimize the downstream reactive oxygen species, which are excessively produced resulting from the infection and inflammatory process, is reported. Catalase assists to regulate production of cytokines, protect oxidative injury, and repress replication of SARS?CoV?2, as demonstrated in human leukocytes and alveolar epithelial cells, and rhesus macaques, without noticeable toxicity. Such a therapeutic can be readily manufactured at low cost as a potential treatment for COVID?19.

» Author: Meng Qin, Zheng Cao, Jing Wen, Qingsong Yu, Chaoyong Liu, Fang Wang, Jianjun Zhang, Fengmei Yang, Yanyan Li, Gregory Fishbein, Sen Yan, Bin Xu, Yi Hou, Zhenbo Ning, Kaili Nie, Ni Jiang, Zhen Liu, Jun Wu, Yanting Yu, Heng Li, Huiwen Zh

» Reference: doi:10.1002/adma.202004901

» Publication Date: 13/09/2020

» More Information

« Go to Technological Watch



AIMPLAS Instituto Tecnológico del Plástico

C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN

PHONE

(+34) 96 136 60 40

EMAIL

Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es